Yan Yu

12PUBLICATIONS
76CO-AUTHORS
Medical roboticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 26, 2026
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

|Jun 22, 2026
RBM10 Deficiency Promotes Anti-PD-1 Resistance in LUAD via STING Alternative Splicing-Driven CCL7 Signaling and Macrophage Polarization.

|Mar 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Sep 18, 2025
Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.

Mingjun Xu, Yan Xu, Yingchun Man

|Jun 17, 2025
Integrating multi-omics to unveil PSMD12 as a critical gene in promoting brain metastases of lung adenocarcinoma.

Xin Li, Juxuan Zhang, Meng Zhang

|May 16, 2025
Phase I/II Study of Tifcemalimab, an Anti-B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.

Ying Cheng, Jie Wang, Yan Yu

Pageof 2

Frequent Collaborators

2 joint publications

Lin Wu

2 joint publications

Ying Cheng

2 joint publications

Jie Wang

2 joint publications

Shun Lu